化合物UK-240455 T13248

Product Introduction
Bioactivity


英文名: UK-240455

描述: UK-240455是一种有效的且具有选择性的 N-甲基 D-天冬氨酸 (NMDA) 甘氨酸受体拮抗剂，具有神经保护作用和改善帕金森病模型的运动的功能，是治疗帕金森病的潜在候选化合物。

体内活性: After i.v. administration of UK-240455 to male rats, UK-240455 exhibits a clearance of 12 mL/min/kg and a volume of distribution of 0.4 L/kg. The plasma concentration of UK-240455 shows a decrease with an apparent half-life of 0.4 h. The analysis of urine (0 to 24 h) reveals that 57% of the administered dose is excreted unchanged. Thus, the urine clearance rate of UK-240455 in rats amounts to 7 mL/min/kg. Upon oral administration to male rats, the apparent elimination half-life of UK-240455 from plasma was observed to be 1.6 hours.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 12 mg/mL (32.59 mM)


关键字: UK240455 | UK-240455 | UK 240455

相关产品: Pregnenolone monosulfate | 1-Aminocyclobutanecarboxylic acid | L-701252 | TCN 213 | Rapastinel acetate | Radiprodil | Riluzole | Rapastinel | Co 101244 hydrochloride | Flutriafol

相关库: Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | Bioactive Compound Library

化合物UK-240455 T13248信息由TargetMol中国为您提供，如您想了解更多关于化合物UK-240455 T13248报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途